

North Central Cancer Treatment Group

N083E: Phase II Safety Study of Docetaxel and Carboplatin in Combination with Trastuzumab and Lapatinib in Early Breast Cancer

Status Change – July 27, 2009

**NOTICE OF STATUS CHANGE**

The safety analysis of the initial group of 10 patients enrolled has been conducted per protocol design. The safety data do not show any increased risks of adverse events from this combination. Therefore, this study will reopen Monday, July 27, 2009.

**Please retain this notice with the protocol.**